HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN

Dave Levitan

Articles

Extending Survival in Extensive-Stage Small-Cell Lung Cancer

September 11, 2019

In this phase III trial, investigators assessed the clinical efficacy and safety of durvalumab with or without tremelimumab with etoposide and carboplatin or cisplatin chemotherapy followed by durvalumab with or without tremelimumab maintenance therapy compared with EP alone as first-line treatment in extensive-stage small-cell lung cancer.

Alectinib Improves PFS, CNS Responses in Crizotinib-Treated ALK+ NSCLC

April 30, 2018

Alectinib offered significantly improved outcomes over standard chemotherapy in patients with ALK-positive non–small-cell lung cancer who had progressed on crizotinib therapy.

Pazopanib Improves PFS in Extensive-Disease SCLC, But Adds Toxicity

February 16, 2018

Maintenance therapy with pazopanib significantly prolonged progression-free survival in patients with extensive-disease small-cell lung cancer, but with toxicity.

T-Cell Therapy With Fludarabine Active in Synovial Sarcoma

November 10, 2017

NY-ESO-1 SPEAR T-cell therapy showed promising results and was reasonably safe in patients with synovial sarcoma, according to a new study. The addition of fludarabine may be important to achieving those positive results.

Developer Applies for Use of CAR T-Cell Therapy in DLBCL

November 06, 2017

Novartis has submitted an application to the FDA to extend the indications for its CAR T-cell therapy tisagenlecleucel (Kymriah) for its use in adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.

Dacomitinib Tops Gefitinib in First-Line EGFR-Mutant NSCLC

October 10, 2017

The second-generation EGFR tyrosine kinase inhibitor dacomitinib significantly improved progression-free survival over gefitinib as a first-line therapy for EGFR–positive non–small-cell lung cancer, according to a randomized phase III trial.